Two things stand out to me that may have contributed.
Point 4: "This result may be related to the stability or performance properties of the specificbatch of commercially sourced assay kits"
and
Point 5: "...In-house development ... expected to reduce the risks of unreliablesupply and test performancevariability associated with commercially available assay kits"
IMO I read this as they are not satisfied with the quality and reliability of externally sourced assay kits, they believe this may have adversely affected the study, however by developing antibodies and reagents in-house they may be able to reduce performance risks associated with external assay kits.
Just a thought, happy to be corrected.
RHY Price at posting:
20.0¢ Sentiment: Buy Disclosure: Held